Bone-targeted agents: preventing skeletal complications in prostate cancer.
about
Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progressionFuture of bisphosphonates and denosumab for men with advanced prostate cancer.Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use.The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
P2860
Bone-targeted agents: preventing skeletal complications in prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 September 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bone-targeted agents: preventing skeletal complications in prostate cancer.
@en
Bone-targeted agents: preventing skeletal complications in prostate cancer.
@nl
type
label
Bone-targeted agents: preventing skeletal complications in prostate cancer.
@en
Bone-targeted agents: preventing skeletal complications in prostate cancer.
@nl
prefLabel
Bone-targeted agents: preventing skeletal complications in prostate cancer.
@en
Bone-targeted agents: preventing skeletal complications in prostate cancer.
@nl
P2860
P1476
Bone-targeted agents: preventing skeletal complications in prostate cancer.
@en
P2093
Alicia K Morgans
Matthew R Smith
P2860
P304
P356
10.1016/J.UCL.2012.07.009
P577
2012-09-04T00:00:00Z